THROMBODYNAMICS ASSAY IN HEALTHY AND DISEASED SUBJECTS
Russian Federation 
Disclosure : A. Balandina Grant / Research support from: HemaCore LLC, E. Lipets Employee of: HemaCore LLC, N. Soshitova Employee of: HemaCore LLC, D. Polokhov Grant / Research support from: HemaCore LLC, S. Vasil’ev Employee of: HemaCore LLC, M. Panteleev: None Declared, F. Ataullakhanov Employee of: HemaCore LLC
[More]
[Less]
You need to have a Flash player to see the MULTIWEBCAST Viewer. Please click on the link below to download Flash Player.
Get Flash Player
11 slide(s) – English – 2012-06-29
THROMBODYNAMICS ASSAY IN HEALTHY AND DISEASED SUBJECTS
A. N. Balandina, E. N. Lipets, N. P. Soshitova, D. M. Polokhov, S. A. Vasil’ev, M. A. Panteleev, F. I. Ataullakhanov
Objectives: We developed a novel in vitro assay for coagulation diagnostics, called thrombodynamics, that takes into account spatially heterogeneity of blood clotting. Here, we attempted to evaluate effects of normal-, hypo- and hypercoagulation plasma samples on thrombodynamics.
Methods: In thrombodynamics fibrin clot formation in a thin layer of nonstirred platelet free plasma where clotting was initiated by a surface with immobilized tissue factor and monitored using videomicroscopy. The following groups were included in the study: 1) 74 healthy subjects, 2) 18 severe hemophilia A patients, 3)10 patients with coronary heart disease undergoing the heparin therapy, 4)12 patients with coronary heart disease undergoing the coumarin therapy, 5) 48 patients with Hodgkin’s disease undergoing the polychemotherapy and 6) 10 patients with cardiac indarction (1-6 h after heart attack). Patients represented the models of hypo- and hypercoagulation conditions, respectively, which was conformed by activated partial thromboplastin time or international normalized ratio.
Results: We monitored the following characteristics: clot initiation (Tlag, time of clot formation near the TF surface), propagation (Vst, rate of fibrin clot propagation) and plasma procoagulant potential (SC, spontaneous clotting outside the clot growth region, and Vst). The value of Tlag differed only in the coumarin therapy group. The Vst significantly increased in hypercoagulation groups and decreased in hypocoagulation groups. Only 2 cases with SC in norma and no SC in hypocoagulation samples was observed, but SC was present in 36% of subjects undergoing polychemotherapy and in 60% of subjects with coronary infarction.
Conclusion: The most sensitive parameters of thrombodynamics to hypo- and hypercoagulation conditions are Vst and SC. The data indicate that this spatially heterogeneous experimental approach has a potential for coagulation diagnostics.
|
|
